Literature DB >> 11683527

Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I.

J Y Reginster1, Y Henrotin, C Christiansen, E Gamwell-Henriksen, J Collette, S Christgau.   

Abstract

Biochemical markers of bone resorption can be used clinically to predict the risk of osteoporosis-related fractures (prognostic tool) and to assess the response of an osteoporotic patient to an antiresorptive therapy (monitoring tool). Our aim was to assess the ability of four currently marketed biochemical markers of bone resorption, based on the measurement of degradation products from collage type I telopeptides to monitor the elevated resorption associated with menopause. Women (846) were stratified for menopause, age, and bone mineral density and the following markers were measured: urinary cross-linked N-telopeptides of type I collagen (NTx), the levels of breakdown products of type I collagen C-telopeptides in serum (S-CTx), and in urine, by ELISA (U-CTx-E), and RIA (U-CTx-R). Furthermore, the ratio (alpha/beta) between the alphaL form of CTx measured in the CTx RIA and the betaL form measured in the ELISA was calculated. The mean difference was calculated for each marker in women with osteopenia (Op) or osteoporosis (PMO) (WHO definition) compared with healthy premenopausal (Pre) women and postmenopausal (N Post) women with normal bone mass. Serum CTx showed the highest elevation in post- compared with premenopausal women. All marker values were significantly higher in Op and PMO subjects compared with both Pre and to N Post women. Compared with premenopausal values, the largest elevation in both Op and PMO women was observed for serum CTx. Compared with N Post, urine NTx showed the highest increase in OP subjects. The alpha/beta CTx ratio was elevated in post- compared with Pre women, but there was no difference in the ratio among N Post, Op, or PMO women. In conclusion, postmenopausal women showed elevated turnover with all bone resorption markers, but with substantial individual variation in resorption levels. Furthermore, the turnover process in postmenopausal women appears to be quantitatively different from the premenopausal stage, apparent as altered alpha/beta CTx ratios.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683527     DOI: 10.1007/s002230020042

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

1.  Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.

Authors:  Shinichi Nagase; Yoshitaka Hashimoto; Maria Small; Michiyo Ohyama; Tomohiro Kuwayama; Steve Deacon
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

2.  A Comparative Study of Bone Scan Findings and Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma.

Authors:  Meera S Ghadge; Purva P Naik; Bijaynath P Tiwari; Ruprekha M Hegde; Tanaji J Matale
Journal:  Indian J Clin Biochem       Date:  2011-09-30

Review 3.  Lead as a Risk Factor for Osteoporosis in Post-menopausal Women.

Authors:  Anjali Manocha; L M Srivastava; Seema Bhargava
Journal:  Indian J Clin Biochem       Date:  2016-08-26

4.  Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.

Authors:  Christina L Addison; Gregory R Pond; Huijun Zhao; Sasha Mazzarello; Lisa Vandermeer; Robyn Goldstein; Eitan Amir; Mark Clemons
Journal:  Springerplus       Date:  2014-10-01

5.  Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study.

Authors:  Anne C Bay-Jensen; Adam Platt; Anne Sofie Siebuhr; Claus Christiansen; Inger Byrjalsen; Morten A Karsdal
Journal:  Arthritis Res Ther       Date:  2016-01-20       Impact factor: 5.156

Review 6.  Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  P Bergmann; J-J Body; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; J-Y Reginster; V Gangji
Journal:  Int J Clin Pract       Date:  2009-01       Impact factor: 2.503

7.  Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

Authors:  Paul Andreas Compare Cloos; Stephan Christgau; Nina Lyubimova; Jean-Jacques Body; Per Qvist; Claus Christiansen
Journal:  Breast Cancer Res       Date:  2003-05-19       Impact factor: 6.466

8.  Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application.

Authors:  Pernille Høegh-Andersen; László B Tankó; Thomas L Andersen; Carina V Lundberg; John A Mo; Anne-Marie Heegaard; Jean-Marie Delaissé; Stephan Christgau
Journal:  Arthritis Res Ther       Date:  2004-02-19       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.